Lapatinib Tablet 250 mg, 500 mg Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 250 mg, 500 mg
Reference Brands: Tykerb® (EU & US)
Category: Oncology Cancer Care
Lapatinib is a targeted therapy for HER2-positive breast cancer, available in 250 mg and 500 mg oral tablets. Marketed as Tykerb® by GlaxoSmithKline, it inhibits the HER2 receptor to prevent cancer cell growth. Available in the US and EU, Lapatinib is sourced by B2B pharmaceutical wholesalers, ensuring reliable supply and GMP-compliant distribution for oncology clinics at competitive prices.
Product Description:
Lapatinib is a targeted cancer therapy used in the treatment of HER2-positive breast cancer. As a tyrosine kinase inhibitor (TKI), it inhibits the HER2 receptor, a key driver of cancer cell growth. Available in 250 mg and 500 mg oral tablets, Lapatinib is marketed under the brand name Tykerb® by GlaxoSmithKline and is also available in generic forms. Widely sourced by B2B pharmaceutical wholesalers in the US and EU, Lapatinib ensures reliable supply for oncology clinics and cancer centers. Its GMP-compliant distribution offers competitive pricing, making it a key player in breast cancer treatment.
Lapatinib Tablet — third party manufacturing & bulk supply
Lapatinib Tablet 250 mg, 500 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Lapatinib Tablet listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Lapatinib Tablet →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Lapatinib is used for the treatment of HER2-positive breast cancer, particularly advanced or metastatic breast cancer. It is often used in combination with other medicines such as capecitabine or letrozole in patients whose cancer overexpresses the HER2 receptor.
Lapatinib is a synthetic small-molecule tyrosine kinase inhibitor that blocks the activity of HER2 (ErbB2) and EGFR (ErbB1) receptors, which are involved in the growth of certain cancer cells.
The most recognized trade names of lapatinib are Tykerb and Tyverb in different global markets.
The original brand was developed and marketed by GlaxoSmithKline, and now multiple pharmaceutical companies manufacture generic lapatinib tablets worldwide.
The generic name of the medicine is lapatinib ditosylate.
The main brand names are Tykerb and Tyverb.
Lapatinib tablets are manufactured in several countries including the United States, European countries, India, and China by approved pharmaceutical manufacturers.
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
